Every material Form 8-K Endovia Health Sciences, Inc. has filed with the SEC since October 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Endovia Health Sciences entered into an addendum on October 22, 2026, to its equity line of credit with C/M Capital Master Fund, LP, raising the total maximum commitment from $35 million to $135 million, including prior sales. The addendum also sets updated terms for sales made beyond the initial 10,875,000 shares already sold and issued under the agreement, which affects how much new common stock the company may issue over time.
Addendum dated October 22, 2026, amends the Securities Purchase Agreement dated September 19, 2025, with C/M Capital Master Fund, LP
Total maximum commitment increases from $35 million to $135 million, inclusive of prior sales
Updated terms apply to sales above the initial 10,875,000 shares sold and issued under the agreement
Original agreement was filed as Exhibit 10.3 to a Form 8-K on September 25, 2025
Endovia Health Sciences amended its equity line of credit agreement with C/M Capital Master Fund, LP, raising the beneficial ownership limit on the investor from 4.99% to 9.99%, effective immediately. The change allows the investor to hold a larger stake under the facility, which could increase potential share issuance and dilution for existing shareholders, though the filing does not state any amount of shares or proceeds.
Beneficial ownership limit raised from 4.99% to 9.99% under the Purchase Agreement, effective October 15, 2026
Parties also waived notice requirements and other provisions inconsistent with the Letter Agreement
Original Securities Purchase Agreement dated September 19, 2025 was filed as Exhibit 10.3 to a September 25, 2025 8-K
Investor's resales are covered by Form S-1 (File No. 333-298112), declared effective August 24, 2026
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined CannEpil qualifies as a minor use for controlling bone cancer pain in dogs, making it eligible to pursue the conditional approval pathway. The product remains investigational and is not approved or conditionally approved, and the company has not given revenue or financial figures in this filing.
FDA Center for Veterinary Medicine determined CannEpil qualifies as a minor use under the MUMS program
Endovia and Lupvindol are scheduled to meet the FDA for a Pre-Submission Conference on November 19, 2026
Company is working toward a potential veterinary launch in 2027, subject to FDA approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Endovia Health Sciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →